Europe’s rare cancer community calls for a more radical approach

The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict close working between researchers, companies, patients and regulators.

Download full article